Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?

Shares of Adma Biologics (ADMA) have gained 5.8% over the past four weeks to close the last trading session at $19.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25 indicates a potential upside of 25.5%. The average comprises four short-term price targets ranging from a low of $24 to a high of $26, with a standard deviation of $0.82. While the lowest estimate indicates an ...